[1]Atkinson TP, Waites KB. Mycoplasma pneumoniae Infections in Childhood[J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014,33(1):92-94.
[2]Gao LW, Yin J, Hu YH, et al. The epidemiology of paediatric Mycoplasma pneumoniae pneumonia in North China: 2006 to 2016[J]. EPIDEMIOLOGY AND INFECTION, 2019,147:e192.
[3]Kannan TR, Baseman JB. ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens[J]. Proc Natl Acad Sci U S A, 2006,103(17):6724-6729.
[4]Ding Y, Chu C, Li Y, et al. High expression of HMGB1 in children with refractory Mycoplasma pneumoniae pneumonia[J]. BMC INFECTIOUS DISEASES, 2018,18(1):439.
[5] National Health Commission of the People’s Republic of China, National Administration of Traditional Chinese Medicine. Guideline for diagnosis and treatment of community-acquired pneumonia in Children (2019 version)[J]. Chinese Journal of Clinical Infectious Diseases, 2019,12(1):6-13.
[6]Experts Group of Pediatric Respiratory Endoscopy, Talent Exchange Service Centerof National Health Commissio, Endoscopy Committee, et al. Guideline of pediatric flexible bronchoscopy in China(2018 version)[J]. Chinese Journal of Applied Clinical Pediatrics, 2018,33(13):983-989.
[7] Yan Y, Wei Y, Jiang W, Hao C. The clinical characteristics of corticosteroid-resistant refractory Mycoplasma pneumoniae pneumonia in children[J]. Sci Rep. 2016;6:39929.
[8] Park S J, Pai K S, Kim A R, et al. Fulminant and Fatal Multiple Organ Failure in a 12-Year-Old Boy With Mycoplasma pneumoniae Infection[J]. Allergy Asthma Immunol Res,2012,4(1):55-57.
[9]Zhang Q. Mechanism and Treatment of Refractory Mycoplasma Pneumoniae Pneumonia in Children [J]. Journal of Pediatric Pharmacy, 2019,25(6):61-63.
[10]Maselli DJ, Medina JL, Brooks EG, et al. The Immunopathologic Effects of Mycoplasma pneumoniae and Community-acquired Respiratory Distress Syndrome Toxin. A Primate Model[J]. Am J Respir Cell Mol Biol, 2018,58(2):253-260.
[11] Li G, Fan L, Wang Y, et al. High co-expression of TNF-alpha and CARDS toxin is a good predictor for refractory Mycoplasma pneumoniae pneumonia[J]. MOLECULAR MEDICINE, 2019,25(1):38.
[12] Shimizu T, Kida Y, Kuwano K. Cytoadherence-dependent induction of inflammatory responses by Mycoplasma pneumoniae[J]. IMMUNOLOGY, 2011,133(1):51-61.
[13] Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000,192(4):565-570.
[14] Kang R, Chen R, Zhang Q, et al. HMGB1 in health and disease[J]. MOLECULAR ASPECTS OF MEDICINE, 2014,40:1-116.
[15] Afkham A, Eghbal-Fard S, Heydarlou H, et al. Toll-like receptors signaling network in pre-eclampsia: An updated review[J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2019,234(3):2229-2240.
[16] Lai JF, Zindl CL, Duffy LB, et al. Critical role of macrophages and their activation via MyD88-NFkappaB signaling in lung innate immunity to Mycoplasma pneumoniae[J]. PLoS One, 2010,5(12):e14417.
[17] Takeda K, Takeuchi O, Akira S. Recognition of lipopeptides by Toll-like receptors[J]. J Endotoxin Res, 2002,8(6):459-463.
[18] Manukyan M, Triantafilou K, Triantafilou M, et al. Binding of lipopeptide to CD14 induces physical proximity of CD14, TLR2 and TLR1[J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2005,35(3):911-921.
[19] Nakata T, Yasuda M, Fujita M, et al. CD14 directly binds to triacylated lipopeptides and facilitates recognition of the lipopeptides by the receptor complex of Toll-like receptors 2 and 1 without binding to the complex[J]. CELLULAR MICROBIOLOGY, 2006,8(12):1899-1909.
[20] He J, You X, Zeng Y, et al. Mycoplasma genitalium-derived lipid-associated membrane proteins activate NF-kappaB through toll-like receptors 1, 2, and 6 and CD14 in a MyD88-dependent pathway[J]. Clinical and Vaccine Immunology, 2009,16(12):1750-1757.